Under Title 17, Section 2500, California Code of Regulations all suspected outbreaks are reportable.
Definition of Outbreak (please take into account all of the footnotes below):
OR
*Laboratory-based molecular tests are also known as nucleic acid amplification tests (NAATs) and can include RT-PCR tests OR Antigen tests. PCR or supervised in-facility Ag, or testing done at another facility, are acceptable. HCP who are already excluded from work due to symptoms/positivity on home test should not report back to facility to be tested, but should continue exclusion from work per guidance and can be counted towards the outbreak case count if they fit the epi-linkage parameters. If opening an outbreak based on positive antigen test results, the positive individuals must be symptomatic.
Please see CDC’s Overview of Testing for SARS-CoV-2 in the healthcare setting for more details on both molecular and antigen tests.
**Epi-linkage among residents is defined as overlap on the same unit or ward, or other resident care location (e.g., radiology suite), or having the potential to have been cared for by common HCP within a 7-day period of each other. Determining epi-linkages requires judgment and may include weighing evidence of whether or not residents had a common source of exposure. Epi-linkage among HCP is defined as having the potential to have been within 6 ft for 15 minutes or longer while working in the facility during the 7 days prior to the onset of symptoms; for example, worked on the same unit during the same shift, and no more likely sources of exposure identified outside the facility. Determining epi-linkages requires judgment and may include weighing evidence of whether or not transmission took place in the facility, accounting for likely sources of exposure outside the facility.
***This second criterion including HCP AND resident cases does not apply to ICFs and CLHFs.
*Symptom onset or positive specimen collection date is considered day 0.
Single confirmed COVID-19 RESIDENT case in a SNF/ICF/CLHF
Confirmed COVID-19 HCP case in a SNF
Visitors:
For the most up to date guidance on visitation in SNFs, please see the Communal Dining, Group Activities, and Visitation section. The facility should identify and inform any visitors if they may have been close contacts to a confirmed infectious case. Visitors who are close contacts should follow instructions for the general public.
Staying up to date with COVID-19 vaccine doses is critical to protecting both residents and staff. The latest COVID-19 vaccine clinical recommendations are located on CDC’s website: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the US. Below are key COVID-19 vaccine guidance and resources for facilities in LA County.
You can also see the CDPH vaccine schedules in English and Spanish. Additional vaccine resources from LAC DPH are located on the DPH Vaccine Resources page.
Offer, Track, and Report COVID-19 Vaccination Doses
Resources for enrolling and reporting in CAIR2 as a front-end user:
Antiviral Treatment
There are highly effective outpatient COVID-19 antiviral treatments to prevent severe outcomes, such as hospitalizations and death, among high-risk individuals infected with COVID-19, particularly including nursing home residents. The preferred outpatient treatment is ritonavir-boosted nirmatrelvir (Paxlovid), an oral antiviral, or intravenous remdesivir. Molnupiravir (Lagevrio) is an alternative if these preferred treatments are not appropriate, feasible to use, or clinically appropriate. See NIH COVID-19 Treatment Guidelines Antiviral Agents Summary Recommendations (available for download until August 16, 2024).
Per CDPH AFL 23-29 (COVID-19 Treatment Resources for SNFs), all SNF residents with a diagnosis of mild to-moderate COVID-19 are eligible for outpatient antiviral treatment and should be evaluated by a prescribing clinician to start treatment. This should also be considered in ICFs and CLHFs. Because the oral antiviral therapies need to be started within five (5) days of symptom onset (remdesivir is within 7 days of symptom onset), it is crucial for prescribing clinicians to assess residents for COVID-19 as soon as they become symptomatic. Residents that are unable to receive Paxlovid should be treated with either remdesivir or molnupiravir if eligible. See LAC DPH’s COVID-19 Outpatient Therapeutics page for more detailed information.
Facilities should not transfer residents to hospitals solely for treatment of mild or moderate COVID-19, unless they are not staffed to care appropriately for positive residents. If a facility or pharmacy supplying therapeutics to a facility is having difficulty obtaining sufficient doses in a timely way, especially during an outbreak, please contact LAC DPH as soon as possible at LACSNF@ph.lacounty.gov or DPH-Therapeutics@ph.lacounty.gov.
To ensure SNFs are compliant with CDPH AFL 23-29 and best practices, they should:
Residents with COVID-19 may also be assessed for and offered IV remdesivir. Given the emergence of variants resistant to monoclonal antibodies, providing remdesivir in the outpatient setting may be of particular importance for facilities with severely immunosuppressed patients or high-risk pediatric populations.
For more information please see LAC DPH’s COVID-19 Outpatient Therapeutics page, CDPH’s COVID-19 Treatment Resources for Providers, or NIH’s Therapeutic Management of Nonhospitalized Adults with COVID-19 for the most up to date information.
Pre-exposure Prophylaxis
Pemivibart is available as an intravenous infusion for some people who are moderately or severely immunocompromised. Please see the CDC’s Clinical Considerations for COVID-19 Treatment and Pre-exposure Prophylaxis in Outpatients website.
The following general and COVID-19 specific recommendations based on the following:
For more information on infection prevention and control (IPC) basics and the difference between standard and transmission-based precautions, visit the CDC’s Infection Control Basics website.
General Requirements
Source Control
Residents
Staff
Visitors
Hand Hygiene (HH)
Transmission Based Precautions and Personal Protective Equipment (PPE)
As detailed below, HCP should follow standard precautions and COVID-19 transmission-based precautions for residents suspected or confirmed to have COVID-19, or who are asymptomatic (close contacts).
Ventilation, Filtration, and Air Quality: Effective ventilation is one of the most important ways to control small aerosol transmission, however, ventilation and other indoor air quality improvements are additions to, and not replacements for, infection prevention and control including any applicable state or local directives. Please carefully review in full the following guidance documents:
Please note SNFs have a second opportunity to apply for Civil Money Penalty (CMP) Reinvestment funds to purchase portable fans and portable room air cleaners with high-efficiency particulate air (HEPA, H-13 or -14) filters to increase air exchange or improve air quality. Facilities should only use portable air cleaners with the involvement of professionals* and following the state guidance above. While portable air cleaners may help when used correctly, facilities should not rely on any single solution to effectively improve the ventilation and air quality of their buildings. Facilities should consult with professionals* to perform comprehensive evaluations of their HVAC (Heating, Ventilation, and Air Conditioning) systems and indoor air quality and obtain permits or approvals from any applicable regulatory bodies as necessary prior to implementing changes.
*Professionals: facilities engineers, mechanical engineers, indoor air quality or industrial hygiene consultants, etc.
Environmental cleaning:
Please refer to CDC guidelines on environmental infection control: https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html#r2.
For a list of EPA-registered disinfectants that have qualified for use against SARS-CoV-2 (the COVID-19 pathogen) go to: https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2. Products should always be used according to manufacturer’s instructions; disinfectants may not have proper effectiveness against SARS-CoV-2 if manufacturer’s instructions are not followed.
The following recommendations for communal dining, group activities, and visitation are based upon the following:
Resident Rights
Facilities may not restrict visitation or suspend communal dining and group activities without a reasonable clinical or safety cause, consistent with resident rights in the federal regulation Title 42 CFR section 483.10(f)(4)(v). To mitigate risks to others, visitation, communal dining, and group activities should be conducted in adherence to the “Core Principles of COVID-19 Infection Prevention” section of CMS QSO 20-39-NH-Revised, and the “Infection Prevention and Control Guidance” section (above) of this guidance.
Communal Dining and Group Activities
Residents who are in isolation, whether suspected and in isolating in-place or confirmed isolation in the dedicated COVID-19 isolation area, should avoid communal dining and group activities regardless of local COVID-19 levels or the facility’s outbreak status. Residents who are close contacts may continue participating in group activities while wearing well-fitting masks with good filtration but should not participate in communal dining through day 10 since their last exposure (day 0 being day of exposure). These activities may take place indoors or outdoors regardless of the facility’s outbreak status and regardless of the resident’s vaccination status. Facilities should continue to follow all infection prevention and control measures to conduct communal dining and group activities safely including but not limited to the following:
Visitation
Table 1. Infection Prevention & Control Measures for Visitation | ||
---|---|---|
Residents Not in Isolation | Residents in Isolation (dedicated COVID-19 isolation area or in-place) | |
Safe Entry Policies |
* Visitors should follow the same criteria used to discontinue isolation for SNF residents (please see table 3). Criteria for the general public does not apply in this setting given the high-risk nature of these facilities and their residents. |
* Visitors should follow the same criteria used to discontinue isolation for SNF residents (please see table 3). Criteria for the general public does not apply in this setting given the high-risk nature of these facilities and their residents. |
Masks | Visitors are strongly recommended to wear well-fitting masks when indoors if:
|
All visitors should be offered an N95 respirator or higher and perform a seal check. Residents should also wear well-fitting masks if safe and practical. |
Other Infection Prevention and Control |
|
|
Physical Distancing | There is no recommendation to physically distance or avoid physical contact (e.g., hugs, holding hands) between a resident and their visitor(s), regardless of vaccination status. However, physical distancing should be followed during large indoor gatherings to avoid crowding especially in poorly ventilated areas. | |
Location of Visit |
|
|
Surveillance. Active symptom screening of residents and staff are the basis of infectious disease surveillance. Prompt identification and management of symptomatic individuals (testing and isolation), including those with mild symptoms, can help mitigate transmission.
Testing Methods: Laboratory-based PCR vs Point-of-care Antigen Testing
Table 2. Summary of Testing Guidance
The table below contains recommendations for COVID-19 testing in SNFs based upon new federal regulations under Title 42 CFR § 483.80(h) as described in CMS QSO 20-38-NH-Revised as well as the CDC “Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the COVID-19 Pandemic” guidance. Please note when there are differences in testing requirements, the most conservative testing guidance should be followed.
NOTE: Interpretation of COVID-19 viral test results does not change after an individual has received COVID-19 vaccination.
Testing Indication | Residents | Staff |
---|---|---|
Symptomatic Individual with symptoms of COVID-19 including mild symptoms, regardless of vaccination status NOTE: If a staff or resident develops new symptoms consistent with COVID-19 ≤ 90 days of a prior positive test and an alternative etiology cannot be identified, then retesting with an antigen test can be considered in consultation with the medical director, infectious disease, or infection control experts. |
One antigen test immediately and if negative, one PCR/NAAT test collected 48 hrs later for a total of at least 2 tests; OR One PCR/NAAT test immediately. During the respiratory virus season, residents with acute respiratory symptoms should also be tested for influenza and other respiratory viruses as per LAC DPH's guidance on management of influenza in context of COVID-19 in SNFs. |
Test immediately. Please see LAC DPH’s COVID-19 Infection Prevention Guidance for Healthcare Personnel. |
Contact Tracing Testing One or more case(s) identified in a resident or staff AND contact tracing is feasible (i.e., exposure is known and limited and there are staffing resources to support rapid contact tracing). |
Serially test residents who are close contacts1 and exposed staff identified in contact tracing 3 times on days 1, 3, and 5 after the last exposure (day 0).
Antigen tests or PCR/NAAT tests (if TAT is <48 hrs) may be utilized. If additional resident case(s) are identified during close contact testing, then the facility should immediately broaden their testing strategy to group-level or facility-level response testing serially every 3-7 days for PCR/NAAT tests (if TAT <48 hrs) or every 3 days for antigen tests until there are no new cases identified among residents or staff for 14 days. Any asymptomatic residents with positive antigen test results (suspect case) must immediately be isolated in place pending results of confirmatory PCR/NAAT tests. Please see “Isolation and Management of Close Contacts” section. |
|
Group-level testing2 involves all residents and staff in the same area (unit, wing, nursing station area, etc.), regardless of vaccination status, when ≥1 case is identified in a resident or staff. This is the recommended initial response testing strategy when the exposure is suspected to be limited to the same area of the facility. Facility-wide testing2 involves all residents and staff in the facility, regardless of vaccination status, when ≥1 case is identified in a resident or staff. This is the recommended initial response testing strategy when widespread exposure is suspected, the exposure level is unknown, or contact tracing is unreliable or unable to be performed in a timely way. |
For initial response testing strategy: serially test on days 1, 3, and 5 after exposure (day 0). If the initial round of testing on days 1, 3, and 5 yields additional cases among residents, then response testing should be further broadened to facility-wide if not done so already. Subsequent rounds of response testing should be every 3-7 days for PCR/NAAT tests (if TAT <48 hrs) or every 3 days for antigen tests until there are no new cases identified among residents or staff for 14 days. Any asymptomatic residents with positive antigen test results (suspected case) should immediately be isolated in place pending results of confirmatory PCR/NAAT testing. Please see “Isolation and Management of Close Contacts” section. |
|
Routine screening testing2: Individuals who are asymptomatic, not a new admission or re-admission, not a close contact, and when there is no facility-wide or group-level post-exposure or response testing. | Generally not recommended, but may be performed at the discretion of the facility. If a facility chooses to conduct routine screening testing, it should not be based on vaccination status and resident rights should be respected (i.e., resident refusal should not result in quarantine or influence their rooming or placement).
NOTE: Facilities should maintain testing capacity and should have the ability to ramp up testing in the event routine screening testing is required at a future date. |
|
New Admissions and Re-Admissions2 who are asymptomatic without a current diagnosis of COVID-19 at the time of admission and without known close contacts.
Residents who have returned after leaving the facility for 24 hours or longer should be managed as an admission. |
Serially testing a total of 3 times on days 0, 3, and 5
after admission (day 0) is a strong recommendation when transmission of respiratory viruses (including SARS-CoV-2) is high
in the community and a consideration when the level is low. Public Health may direct individual facilities on a case-by-case basis to test all admissions and re-admissions to help control an outbreak.
Antigen tests or PCR/NAAT tests (if TAT is <48 hrs) may be utilized. If admission testing is performed, follow guidance in “Isolation and Management of Close Contacts” section. |
Not applicable. |
Footnotes:
Retesting Previously Positive Staff/Residents
|
Refusal of Testing
Please refer to CMS QSO 20-38-NH-Revised. The following are some clarifications for resident refusal of testing:
The following summary of isolation, management of close contacts, and related infection control guidance is based on CDPH AFL 23-12, CMS QSO 20-38-NH-Revised, and the CDC guidance “Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic.”
Table 3. Summary of Isolation and Infection Control Guidance for Residents
Who | Infection Control Measures |
---|---|
Confirmed COVID-19 Case |
|
Suspected COVID-19 Case:
|
|
Close contacts (asymptomatic) |
|
Residents undergoing group-level or facility-wide post-exposure and response testing who are asymptomatic and not part of the above categories |
|
New admission, re-admissions, or returning after leaving the facility >24 hrs who are asymptomatic and not part of the above categories |
|
Footnotes: * Special staffing considerations for the designated COVID-19 Isolation Area:
**The following are considered severely immunocompromising conditions as per CDC: actively receiving chemotherapy for cancer, hematologic malignancies, being within one year from receiving a hematopoietic stem cell or solid organ transplant, untreated HIV infection with CD4 count <200, combined primary immunodeficiency disorder, taking immunosuppressive medications (e.g., drugs to suppress rejection of transplanted organs or to treat rheumatologic conditions such as mycophenolate, rituximab, prednisone dose >20mg/day for more than 14 days), or other severely immunocompromised condition as determined by the resident’s primary/treating physician. |
Facilities should follow the LAC DPH COVID-19 Infection Prevention Guidance for Healthcare Personnel.
Symptom monitoring
Return to work
Facilities should communicate COVID-19 status (suspect or confirmed infection) to the receiving facility (hospital, outpatient clinic, dialysis center, dental clinics) before transfer as per CDC. Healthcare facilities are strongly encouraged to use the LAC DPH Infectious Organism Transfer Form.
During outbreaks, SNFs should communicate with their Public Health outbreak investigation team prior to any lateral transfer to another SNF. On a case-by-case basis, Public Health may restrict lateral transfers to other SNFs during outbreaks, especially of residents who are suspected or confirmed COVID-19 cases.
Receiving SNFs should not require a negative test result for COVID-19 as criteria for admission or readmission. Instead, SNFs and hospitals should proactively communicate and collaborate to facilitate the safe, timely, and appropriate placement of SNF residents. SNFs should be prepared to provide care safely without putting existing residents at risk, including maintaining the ability to quickly re-establish a designated COVID-19 isolation area (formerly known as a “Red Zone”) as per CDPH AFL 23-12. Please reach out to LAC DPH at LTC_NCoV19@ph.lacounty.gov for questions and/or help with transfers related to COVID-19 infection control.
In cases of hospital overload, this transfer guidance may be adjusted by LAC DPH.Once an outbreak has been identified, facilities should immediately implement the following measures.
AND
For facilities that are conducting response driven testing
Facilities are required to report all positive test results from point-of-care SARS-CoV-2 antigen tests, any suspected COVID-19 outbreak*, and all fatalities associated with COVID-19 within 24 hours including out of facility/hospital deaths of presumed cases and all deaths that occurred during an active COVID-19 outbreak, regardless of testing.
*Please note that the current COVID-19 outbreak definition in SNFs in Los Angeles County is at least one PCR laboratory confirmed case (symptomatic or asymptomatic) of COVID-19 in a SNF resident who has resided in the facility for at least 7 days.
For more details, please see the LAC DPH COVID-19 Case Reporting Protocol for SNFs flowchart.